This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Onconetix Gestione

Gestione criteri di controllo 0/4

Onconetix's Il CEO è Ralph Schiess, nominato in Dec2023, ha un mandato di meno di un anno. possiede direttamente 0.91% delle azioni della società, per un valore di € 40.73K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 1.6 anni.

Informazioni chiave

Ralph Schiess

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	0.9%
Durata media del management	1.6yrs
Durata media del Consiglio di amministrazione	1.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Ralph Schiess (45 yo)

less than a year

Mandato

Dr. Ralph Schiess, Ph D., serves as Chief Science Officer at Onconetix, Inc. since December 15, 2023 and serves as its Interim Chief Executive Officer since January 12, 2024. He Co-founded ProteoMediX AG i...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ralph Schiess	Interim CEO & Chief Science Officer	less than a year	Nessun dato	0.91% € 23.3k
Karina Fedasz	Interim Chief Financial Officer	less than a year	Nessun dato	Nessun dato
Brian Price	Head of Technology Strategy	4yrs	US$126.48k	Nessun dato
Frank Jaeger	Senior VP of Marketing & Business Development	1.6yrs	Nessun dato	Nessun dato
Andrew Skibo	Global Head of Biologics Operations	3.3yrs	Nessun dato	Nessun dato
Theodore Yoho	Head of Business Development	3.3yrs	Nessun dato	Nessun dato
Ali Fattom	Head of Science & Discovery	2yrs	Nessun dato	Nessun dato
Jay Newmark	Chief Medical Officer	1.4yrs	Nessun dato	Nessun dato
Christian Bruhlmann	Chief Strategy Officer & GM of Europe	less than a year	Nessun dato	0.79% € 20.4k
Donald Very	Senior VP of Commercial Research & Development	no data	Nessun dato	Nessun dato

1.6yrs

Durata media

49yo

Età media

Gestione esperta: Il team dirigenziale di J4T non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
John Rice	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Thomas Meier	Director	less than a year	Nessun dato	Nessun dato
James Sapirstein	Non Executive Chairman & Lead Independent Director	2.6yrs	US$182.12k	0.021% € 549.3
Ajit Singh	Independent Director	less than a year	Nessun dato	0.010% € 269.9
Sunetra Gupta	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Simon Tarsh	Independent Director	2.1yrs	US$112.62k	0.021% € 549.3
Timothy Ramdeen	Independent Non-Executive Director	1.7yrs	US$82.67k	0.021% € 549.3

1.7yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di J4T non è considerato esperto (durata media del mandato 1.6 anni), il che suggerisce un nuovo consiglio.

This company listing is no longer active

Onconetix Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

High number of new and inexperienced directors

Recent updates

Onconetix Provides Non-Compliance Update

Onconetix, Inc. announced that it expects to receive $5 million in funding

Onconetix, Inc. announced delayed 10-Q filing

Onconetix, Inc., Annual General Meeting, Sep 05, 2024

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Dr. Neil J. Campbell as CEO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

CEO, President & Executive Chairman recently sold €2.7m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

High number of new and inexperienced directors

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

High number of new and inexperienced directors

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media